Published in final edited form as:

Bioorg Med Chem Lett. 2016 May 15; 26(10): 2481–2488. doi:10.1016/j.bmcl.2016.03.102.

Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D₄R) antagonists

Jonathan O. Witt^a, Andrea L. McCollum^a, Miguel A. Hurtado^b, Eric D. Huseman^a, Daniel E. Jeffries^a, Kayla J. Temple^a, Hyekyung C. Plumley^{b,c}, Anna L. Blobaum^{b,c}, Craig W. Lindsley^{a,b,c}, and Corey R. Hopkins^{a,b,c,*}

^aDepartment of Chemistry, Vanderbilt University, Nashville, TN 37232, United States

^bDepartment of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, United States

^cVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232, United States

Abstract

Herein, we report the synthesis and structure–activity relationship of a series of chiral alkoxymethyl morpholine analogs. Our efforts have culminated in the identification of (*S*)-2-(((6-chloropyridin-2-yl)oxy)methyl)-4-((6-fluoro-1*H*-indol-3-yl)methyl)morpholine as a novel potent and selective dopamine D₄ receptor antagonist with selectivity against the other dopamine receptors tested (<10% inhibition at 1 μ M against D₁, D_{2L}, D_{2S}, D₃, and D₅).

Keywords

Dopamine 4 receptor; Antagonist; Morpholine; L-DOPA-induced dyskinesia; Dopamine Selectivity

Dopamine (DA) is a major neurotransmitter and is the primary endogenous ligand for the dopamine receptors. Dopamine receptors are members of the Class A G-protein coupled receptors. There are five dopamine receptor subtypes which are subdivided into two families, the D₁-like family and the D₂-like family. The D₁-like family consists of the D₁ and D₅ receptor subtypes which are coupled to G_s and mediate excitatory neurotransmission. The D₂-family consists of three receptor subtypes (D₂, D₃, and D₄) which are coupled to G_i/G_o and mediate inhibitory neurotransmission. Of the subtypes, the dopamine D₄ receptor (D₄R) has received considerable attention as a potential target for pharmacological intervention due to disorders linked to dysfunction of this receptor (schizophrenia^{1–3}, Parkinson's disease^{4,5}, and substance abuse^{6–8}).

Recently, we reported on the identification of a chiral morpholine scaffold as a potent and selective D₄R antagonist, ML398 (Fig. 1).^{9,10} ML398 was active in vivo; however, the SAR analysis was limited due to the synthetic feasibility of modification of the upper right-hand

*Corresponding author. Tel.: +1 615 936 6892; fax: +1 615 778 1414. corey.r.hopkins@vanderbilt.edu (C.R. Hopkins).

phenethyl group. Thus, we wanted to evaluate alternative linker groups in order to more fully explore the SAR around both the *N*-linked groups as well as moieties adjacent to the oxygen group of the morpholine.

To this end, we set out to replace the ethyl linker with a hydroxymethyl group as this would allow for significant diversification of this portion of the molecule.¹¹ In addition, as we have shown previously, the activity of the chiral morpholine scaffold resides in the (*S*)-enantiomer and the starting Boc-protected (*S*)-2-(hydroxymethyl)morpholine is commercially available. The synthetic procedure to access these compounds is shown in Scheme 1. The *tert*-butyl (*S*)-2-(hydroxymethyl)morpholine-4-carboxylate, **1**, was coupled with the appropriate aryl bromide, **2**, under copper mediated conditions to afford **3**.¹² Alternatively, the aryl ethers could be formed under Mitsunobu conditions¹³ (ArOH, PPh₃, DIAD, μ W, 180 °C) in good yield. Next, the Boc group was removed under acidic conditions and reductive amination with polymer bound CNBH₃ provided the final compounds in modest overall yields.¹⁴

The first set of analogs that we synthesized and evaluated kept the upper right-hand portion constant as the unsubstituted phenoxy moiety and modified the southern nitrogen substituents. A key component for the design of the molecules was to lower the *cLogP* of the compounds since ML398 was rather lipophilic (*cLogP* = 5.10), with a design on potency and pharmacokinetic parameters. The 4-chlorobenzyl, **4a**, direct comparator to ML398 (*K_i* = 36 nM) was equipotent to its predecessor compound (*K_i* = 42 nM) and the introduction of an ether linker led to a significant improvement (lowering) of the *cLogP* (5.10 vs. 3.73).¹⁰ Further substitution around the benzyl group led to a more active compound (3,4-dimethyl, **4b**, *K_i* = 12.3 nM). Additional steric bulk was well tolerated as the naphthyl group was active as well (**4d**, *K_i* = 17.8 nM). Interestingly, the 2-substituted quinoline, **4e**, was significantly less potent (*K_i* = 310 nM) compared to the naphthyl group. Multiple substitution patterns around the phenyl group are well tolerated (**4f–4s**) with a few notable exceptions. Namely, the 3-chloro-4-fluorophenyl (**4f**, *K_i* = 170 nM) and 3, 4-difluorophenyl (**4h**, *K_i* = 150 nM) were less potent than the other analogs tested. The transposed 4-chloro-3-fluorophenyl (**4g**, *K_i* = 19.1 nM) and the 3,4-dichlorophenyl (**4i**, *K_i* = 27 nM) were more active by ~10-fold, suggesting the 4-fluoro substitution is not as well tolerated. However, this is not a fully general phenomenon as the 3-methoxy-4-fluoro analog, **4m**, is one of the most potent compounds in this series (*K_i* = 11.6 nM), along with the 3-methoxy-4-chloro compound (**4p**, *K_i* = 11.6 nM) and 4-methoxy-3-chloro (**4n**, *K_i* = 10.4 nM). As an additional confirmation of the (*S*)-enantiomer activity, the (*R*)-enantiomer of **4n** was made and evaluated, and it was not active (**4o**, 35% inhibition at 10 μ M). In addition to substituted benzyl groups in the southern portion of the molecule, heteroaryl moieties were also well tolerated. The imidazo[1,5-*a*]pyridine, **4u** (*K_i* = 35 nM), was equipotent with ML398; however, the imidazo[1,2-*a*]pyridine, **4t** (*K_i* = 160 nM) was less potent. Moving to the 3-substituted indole compounds yielded the most active compounds in this set of analogs. The 6-chloro (**4aa**, *K_i* = 2.2 nM), 6-methoxy (**4dd**, *K_i* = 5.4 nM) and 6-fluoro (**4ee**, *K_i* = 5.2 nM) were all productive changes. The corresponding 5-substituted indole compounds were not as active (**4bb** and **4cc**), nor was a 4-substituted analog (**4ff**).

Next, we turned our attention to the alkoxy substituents (*R*², Table 2) in conjunction with the southern fragments (*R*¹, Table 1). Initial evaluation utilized the 4-chlorobenzyl and 4-

methoxybenzyl groups as these were shown to be potent antagonists of the D₄R. The first analogs tested were 5-pyrimidine and 2-pyrimidine replacements for the phenyl group. Neither of these replacements led to active compounds; although **5a** did show weak activity (76% inhibition at 10 μ M), and introduction of these polar groups led to a significant lowering of the *cLogP*, as expected. However, removal of one of the nitrogen atoms in the 5-pyrimidine analog led to the 3-pyridine analog and resulted in significant recovery of the potency (**5e**, K_i = 47 nM; **5f**, K_i = 59 nM). Similar removal of a nitrogen atom in the 2-pyrimidine series leaving the 2-pyridine analogs only led to modest recovery of the potency in one of the analogs (**5g**, K_i = 730 nM). Substituted 3- or 4-methoxy groups on the phenyl ether were comparable in activity to the unsubstituted phenethyl derivatives (**5p–5r**). The 3-fluoro and 4-fluoro substituted compounds were well tolerated resulting in very potent compounds (**5k**, K_i = 10.4 nM; **5l**, K_i = 13.1 nM; **5m**, K_i = 10.8 nM; **5n**, K_i = 10.1 nM). Unexpectedly, the 2-halogen-6-alkoxypyridine compounds were active; unlike the 2-alkoxypyridine analogs (vide supra). In fact, combining the 6-fluoro-3-indole analog (**4ee**) with the 2-chloro-6-alkoxypyridine led to one of the most potent compounds from this series (**5y**, K_i = 3.3 nM). Lastly, two compounds in which the sulfide linker replaced the alkoxy linker were synthesized; this proved to be a fruitful change as well (**5aa**, K_i = 9.4 nM; **5bb**, K_i = 7.4 nM).

Having identified a number of active D₄R antagonists, we next wanted to profile these compounds against the other dopamine receptors (D₁, D_{2L}, D_{2S}, D₃, and D₅) (Table 3). Generally speaking, the compounds are selective against the D₁-like family of receptors (D₁ and D₅), both the phenoxy (**4**) and substituted phenoxy or heteroarylalkoxy compounds (**5**) are selective against the D₁-like family of receptors. The compounds are less selective for the D₂-like family, specifically the D_{2S} and D_{2L} receptors. That being said, a number of compounds prove completely selective against all of the dopamine receptors (Table 3), despite high sequence homology. Notably, the 6-fluoro-3-indole compound (**4ee**) showed activity against both D_{2L} and D_{2S} (78% and 76%, respectively). However, the comparator 2-halogen-6-alkoxypyridine compounds (**5u** and **5y**) were fully selective against all of the dopamine receptors tested. Gratifyingly, **5y** is one of the most potent analogs that was made and tested. In addition, the sulfide analogs were also selective (**5aa** and **5bb**).

Having identified a number of potent and selective compounds, we further profiled selected compounds in a battery of Tier 1 in vitro DMPK assays (Table 4). The intrinsic clearance (CL_{INT}) was assessed in liver microsomes (rat and human), and many of the compounds proved to be unstable to oxidative metabolism and were predicted to display high clearance in both species.¹⁵ However, a few compounds were shown to have moderate predicted clearance, such as **4t** (imidazo[1,2-*a*]pyridine) and **4g** (3-fluoro-4-chlorophenyl), which presumably can block oxidation of the phenyl group. Utilizing an equilibrium dialysis approach, the protein binding of the compounds was evaluated in both human and rat plasma. The fraction unbound (F_u) ranged from low to moderate, and these values loosely correlated with the calculated *logP* of the compounds. Although it is understood that fraction unbound is a difficult parameter to SAR around, lowering *cLogP* within a series can tend to produce better values. As such, **4t**, **4l**, and **4y** had the highest fraction unbound and the lowest *cLogP* values. Lastly, we assessed the ability of these compounds to cross the blood–

brain barrier in a rodent IV cassette experiment to determine brain-to-plasma ratios (K_p).^{16,17} A selection of compounds is shown in Table 3, and, although the compounds show high clearance in rat, the compounds are able to cross the BBB with K_p values >2.

In order to better understand the nature of the instability in liver microsomes in both human and rat, we analyzed **5y** in a metabolic soft-spot experiment (Q² Solutions, www.q2labsolutions.com). **5y** was highly metabolized in both rat and human liver microsomal samples in the presence of NADPH. Compound B was the major metabolite in the rat microsomes (*N*-dealkylation + oxidation), and the major metabolite in human microsomes was Compound A (*N*-dealkylation). The parent compound, **5y**, was observed in the rat and human samples in the absence of NADPH. Thus, further analog work will concentrate on blocking the *N*-dealkylation mechanism of metabolism (see Fig. 2).

In conclusion, we have further elaborated our initial D₄R antagonist, ML398, by changing the ethyl linker to a hydroxymethyl linker on the chiral morpholine scaffold. A number of compounds are very potent (D₄ K_i <20 nM) with excellent selectivity against the other dopamine receptors. Notably, compounds **5y**, **5aa**, and **5bb** were shown to have D₄ K_i s <10 nM and be completely selective against the other dopamine receptors (K_i s >10 μ M, ie., >1000-fold selectivity). Compounds **4ee** and **5y** are intriguing molecules as they contain molecular handles and possess desirable physicochemical properties (*cLogP*) for potential radioligand development. Many of the compounds identified were highly cleared in both human and rat liver microsomes, and we have shown that *N*-dealkylation is a major contributor to the instability. Lastly, compounds from this scaffold class are highly brain penetrant as assessed in a rodent IV cassette experiment to determine brain-to-plasma ratios (K_p values >2). Further optimization and in vivo behavioral efficacy experiments will be disclosed in due course.

Acknowledgments

The authors would like to thank the Michael J. Fox Foundation for Parkinson's Research for research support for CRH (MJFF Grant ID: 10000) and Jarrett Foster, Sichen Chang, and Xiaoyan Zhan for their contributions to the DMPK screening tier.

References and notes

1. Lahti RA, Roberts RC, Cochrane EV, Primus RJ, Gallager DW, Conley RR, Tamminga CA. *Mol. Psychiatry*. 1998; 3:528. [PubMed: 9857979]
2. Sanyal S, Van Tol HHM. *J. Psychiatry Res.* 1997; 31:219.
3. Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. *Trends Pharm. Sci.* 1997; 18:186. [PubMed: 9226994]
4. Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. *Behav. Pharmacol.* 2015; 26:101. [PubMed: 25303957]
5. Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. *J. Pharmacol. Exp. Ther.* 2012; 342:576. [PubMed: 22619253]
6. Di Ciano P, Grandy DK, Le Foll B. *Adv. Pharmacol.* 2014; 69:301. [PubMed: 24484981]
7. Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PRA. *Nat. Rev. Neurosci.* 2015; 16:305. [PubMed: 25873042]
8. Koob GF, Volkow ND. *Neuropsychopharmacology.* 2010; 35:217. [PubMed: 19710631]
9. O'Reilly MC, Lindsley CW. *Org. Lett.* 2012; 14:2910. [PubMed: 22616979]

10. Berry CB, Bubser M, Jones CK, Hayes JP, Wepy JA, Locuson C, Daniels JS, Lindsley CW, Hopkins CR. ACS Med. Chem. Lett. 2014; 5:1060. [PubMed: 25221667]
11. Audouze K, Nielsen EØ, Peters D. J. Med. Chem. 2004; 47:3089. [PubMed: 15163190]
12. Altman RA, Shafir A, Lichtor PA, Buchwald SL. J. Org. Chem. 2008; 73:284. [PubMed: 18044928]
13. Mitsunobu O. Synthesis. 1981:1.
14. *Experimental Procedure for the synthesis of 5y*: *tert*-Butyl (*S*)-2-(hydroxymethyl)morpholine-4-carboxylate, 1, (110.0 mg; 0.507 mmol) and DMF (2.5 mL) were added to a vial equipped with a stir bar. The mixture was cooled to 0 °C and then NaH (24.3 mg; 0.608 mmol) was added and the mixture was stirred until fully dissolved. Next, 2-chloro-6-fluoropyridine (133.3 mg; 1.013 mmol) was added and then the reaction mixture was warmed to 60 °C. After 90 min, the reaction was cooled to rt and CH₂Cl₂ was added along with 5% LiCl in H₂O. The layers were separated and the organic layer was dried (MgSO₄) and collected and concentrated. The crude product was purified via flash column chromatography (5–30% EtOAc/hexanes) to provide the *N*-Boc product. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (1H, t, *J* = 8.0 Hz), 6.84 (1H, d, *J* = 7.5 Hz), 6.64 (1H, d, *J* = 8.0 Hz), 4.28 (2H, d, *J* = 4.9 Hz), 3.87 (2H, d, *J* = 10.6 Hz), 3.72–3.69 (2H, m), 3.51 (1H, dt, *J* = 11.6, 2.7 Hz), 2.92 (1H, t, *J* = 22.3 Hz), 2.76 (1H, s), 1.40 (9H, s). The product was treated with 2.0 mL of 4 M HCl/dioxanes and stirred at rt for 30 min. At this time, the mixture was concentrated and the material was converted to the free base via an SCX column. The material was added to a microwave vial along with MP-CNBH₃ (88.2 mg; 2.28 mmol/g polymer; 0.201 mmol), acetic acid (23.0 μL; 0.402 mmol) and CH₂Cl₂ (1.0 mL) and then heated in a microwave at 110 °C for 7 min. The reaction mixture was cooled to rt, filtered and washed with CH₂Cl₂ and purified by flash column chromatography (5–30% EtOAc/hexanes) leaving the desired compound (12.0 mg; 0.0320 mmol; 42%). [α]_D +18.84 (c 1.0, CH₃OH); LCMS: R_T = 0.786 min, >98% @ 254 nm, *m/z* = 376.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (1H, br s), 7.60 (1H, dd, *J* = 8.7, 5.5 Hz), 7.42 (1H, t, *J* = 7.7 Hz), 7.03 (1H, d, *J* = 1.4 Hz), 6.97 (1H, dd, *J* = 9.6, 2.0 Hz), 6.84–6.79 (1H, m), 6.63 (1H, d, *J* = 8.2 Hz), 4.24–4.22 (2H, m), 3.86 (2H, br d, *J* = 10.9 Hz), 3.68–3.65 (1H, m), 2.80 (1H, d, *J* = 11.1 Hz), 2.68 (1H, d, *J* = 11.4 Hz), 2.17 (1H, dt, *J* = 11.4, 3.2 Hz), 2.00 (1H, t, *J* = 10.6 Hz); ¹³C NMR (400 MHz, CDCl₃) δ 163.2, 161.3, 158.9, 148.1, 140.6, 136.3, 124.3, 123.8, 120.5, 116.5, 109.5, 108.5, 97.5, 74.1, 67.6, 66.9, 54.8, 54.0, 52.9.
15. Obach RS. Drug Metab. Dispos. 1999; 27:1350. [PubMed: 10534321]
16. Smith NF, Raynaud FI, Workman P. Mol. Cancer Ther. 2007; 6:428. [PubMed: 17308044]
17. Bridges TM, Morrison RD, Byers FW, Luo S, Daniels JS. Pharmacol. Res. Perspect. 2014;2. [PubMed: 25505573]

Figure 1.
Structure of previously disclosed chiral morpholine D₄ antagonist, ML398.

Figure 2.
Metabolic soft-spot analysis of **5y** in liver microsomes.

Scheme 1.

Reagents and conditions: (a) CuI, Me₄Phen, Cs₂CO₃, toluene (14–30%); (b) ArOH, PPh₃, DIAD, benzene, rt (51%); (c) ArOH, PS-PPh₃, DIAD, THF, rt (21–25%); (d) ArOH, PPh₃, DIAD, THF, μW , 180 °C, 5 min (62%); (e) 4 M HCl in dioxanes; (f) polymer bound CNBH₃, R¹CHO, acetic acid, DCM (16–42%).

Table 1Structure and D₄ activity of the *N*-linked analogs

4a-ff

Compound	R	<i>cLogP</i> ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
ML398		5.10	130	36
4a		3.73	150	42
4b		3.68	45	12.3
4c		3.08	160	44
4d		4.40	64	17.8
4e		3.15	1110	310
4f		3.84	62	170
4g		3.84	69	19.1
4h		3.54	530	150
4i		4.35	97	27
4j		4.21	58	16.2
4k		4.21	320	89
4l		3.18	56	14.3

Compound	R	<i>cLogP</i> ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
4m		3.18	42	11.6
4n		3.70	38	10.4
4o	(<i>R</i>)- 4n	3.70	35% ^c	
4p		3.70	42	11.6
4q		4.48	180	51
4r		3.04	150	43
4s		3.75	58	16.1
4t		2.89	590	160
4u		3.51	130	35
4v		3.73	65	18.1
4w		3.77	130	37
4x		3.83	260	72
4y		3.20	170	47

Compound	R	<i>cLogP</i> ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
4z		3.77	58	15.9
4aa		4.39	8.0	2.2
4bb		3.73	460	130
4cc		4.39	130	37
4dd		3.73	19.5	5.4
4ee		3.87	18.9	5.2
4ff		3.87	3830	1060

^aCalculated using Dotmatics Elemental (www.dotmatics.com/products/elemental).

^bIC₅₀ and K_i values were run in duplicate in a radioligand binding assay using Spiperone at EuroFins (www.EuroFins.com).

^c% inhibition at 10 μM.

Table 2

Structure and D₄ activity of the O- and N-linked analogs

Compd	R ¹	R ²	cLogP ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
ML398			5.10	130	36
5a			1.83	76% ^c	
5b			1.17	—4% ^c	
5c			2.33	31% ^c	
5d			1.67	8% ^c	
5e			2.42	103	47
5f			1.77	210	59
5g			2.83	2,630	730
5h			2.17	57% ^c

Compd	R ¹	R ²	cLogP ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
5a-bb					
5i			2.79	34% ^c	
5j			2.79	37% ^c	
5k			3.84	38	10.4
5l			3.18	47	13.1
5m			3.80	39	10.8
5n			3.80	37	10.1
5o			3.18	92	26
5p			3.70	150	42
5q			3.04	380	110

Compd	R ¹	R ²	cLogP ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
5r			3.70	130	36
5s			3.41	100	28
5t			3.41	130	36
5u			3.47	76	21
5v			3.33	460	130
5w			3.30	260	73
5x			3.30	–3% ^c	
5y			3.99	11.9	3.3
5z			3.85	100	29

Compd	R ¹	R ²	cLogP ^a	IC ₅₀ (nM) ^b	K _i (nM) ^b
5aa			4.41	34	9.4
5bb			4.35	27	7.4

^a Calculated using Dotmatics Elemental (www.dotmatics.com/products/elemental).

^b IC₅₀ and K_i values were run in duplicate in a radioligand binding assay using Spiperone at EuroFins (www.EuroFins.com).

^c % inhibition at 10 μM.

Table 3

Dopamine receptor selectivity of select compounds

Compound	D ₄ (nM)	% inhibition at 10 μ M ^a				
		D ₁ (%)	D _{2L} (%)	D _{2S} (%)	D ₃ (%)	D ₅ (%)
4b	12.3			<50		
4l	14.3	<50	78	76		<50
4n	10.4			<50		
4p	11.6	<50	52	60		<50
4u	35			<50		
4v	18.1			<50		
4z	15.9	<50	64	64		>50
4aa	2.2	<50	94	93	70	<50
4dd	5.4	<50	87	82	70	<50
4ee	5.2	<50	78	76		<50
5k	10.4	<50	83	79	51	<50
5l	13.1	<50	88	82	76	<50
5m	10.8			<50		
5n	10.1			<50		
5u	21			>50		
5y	3.3			<50		
5aa	9.4			<50		
5bb	7.4			<50		

^a % inhibition values were run in duplicate in a radioligand binding assay at EuroFins (www.EuroFins.com).

Table 4

In vitro and in vivo DMPK results of select compounds

Compound	D ₄ (nM)	Microsome intrinsic clearance (mL/min/kg)		Plasma unbound fraction (<i>F_u</i>)	
		hCL _{INT}	rCL _{INT}	Human	Rat
4a	12.3	147	4518	0.007	0.007
4g	19.1	65.3	251	0.006	0.012
4i	27	50.5	621	0.002	0.006
4j	16.2	50.5	247	0.002	0.007
4l	14.3	71.9	2128	0.031	0.037
4n	10.4	78.7	1597	0.010	0.019
4p	11.6	79.7	1505	0.010	0.025
4t	160	17.3	154	0.057	0.215
4y	47	60.5	433	0.039	0.074
4z	15.9	135	3137	0.035	0.069
4aa	2.2	46.7	614	0.006	0.010
4dd	5.4	31.6	184	0.037	0.075
4ee	5.2	71.1	1686	0.017	0.047
5m	10.8	93.0	1499	0.006	0.013
5n	10.1	68.9	1774	0.011	0.014
5u	21	101	4010	0.009	0.015
5y	3.3	230	4195	0.015	0.016
5z	29	98.2	5313	0.004	0.008
5aa	9.4	122	3217	0.008	0.005
5bb	7.4	366	6436	0.001	0.004

Rodent IV cassette (0.25 mg/kg, 0.25 h)

	Plasma (ng/mL)	Brain (ng/g)	<i>K_p</i>
4a	42.5	197	4.62
4l	14.7	108	7.38
4y	37.3	83.1	2.23

Rodent IV cassette (0.25 mg/kg, 0.25 h)				
	Plasma (ng/mL)	Brain (ng/g)	K_p	
4aa	74.8	246	3.29	
5aa	26.1	131	5.03	
5bb	23.1	132	5.73	